Park Ha Biological Technology Co., Ltd. Investment Guide

This summary offers investors a clear overview of Park Ha Biological Technology Co., Ltd.'s performance and outlook, drawing from its annual report for the fiscal year ended October 31, 2025. Incorporated in the Cayman Islands, Park Ha operates primarily from Wuxi, Jiangsu Province, China. Its shares trade publicly on the Nasdaq Capital Market under the ticker symbol BYAH.

Business Overview & Operations: Park Ha Biological Technology researches, develops, and commercializes advanced biological skincare products and medical aesthetic services. Its product portfolio features proprietary anti-aging serums, dermatological treatments, and high-performance beauty devices, primarily distributed through its network of owned and affiliated beauty salons. The company operates through a complex structure, including subsidiaries like Park Ha HK (Hong Kong), Park Ha Investment (Wuxi) Co., Ltd. (a Wholly Foreign-Owned Enterprise or WFOE), and Jiangsu Park Ha Biological Technology Co., Ltd. Crucially, Park Ha controls key operational assets, including prominent beauty salon brands such as Xinyuexuan, Aimeihui, and Xuanyayue Beauty Salons, through Variable Interest Entity (VIE) agreements. This VIE structure, common for Chinese companies seeking overseas listings, allows Park Ha to consolidate these entities' financial results despite foreign ownership restrictions in certain Chinese sectors. While this structure provides operational control, investors should note the inherent legal and regulatory risks. They do not directly own equity in the VIEs.

Financial Performance (Fiscal Year Ended October 31, 2025): Park Ha achieved robust growth during the fiscal year, reporting total revenues of approximately $85.5 million, a 22% increase over the previous fiscal year. Increased customer traffic and higher average transaction values across its beauty salon network, coupled with successful new product launches, primarily drove this growth. Net income reached $12.3 million, a 15% year-over-year increase, resulting in a healthy net profit margin of 14.4%. Gross profit margin stood at 45%, indicating effective cost management.

Financial Health: The company maintains a solid financial position. As of October 31, 2025, Park Ha held $35.2 million in cash and cash equivalents, providing ample liquidity for operations and strategic investments. Total debt remained manageable at $18.7 million, resulting in a favorable debt-to-equity ratio of 0.25. The company's current ratio of 2.1x suggests strong short-term liquidity, demonstrating its ability to meet immediate financial obligations.

Management's Discussion and Analysis (MD&A) Highlights: Management attributes Park Ha's robust financial performance in fiscal year 2025 to strategic initiatives and favorable market conditions. The 22% increase in total revenues stemmed primarily from successful market penetration, evidenced by increased customer traffic and higher average transaction values across the company's expanding beauty salon network. Additionally, the successful launch of three new anti-aging product lines in Q3 2025 significantly boosted revenue growth and enhanced the company's product portfolio. A 15% improvement in net income reflects effective cost management strategies, which helped maintain a healthy gross profit margin of 45% and a net profit margin of 14.4%.

Operationally, the year saw significant achievements in regulatory compliance, including the successful consolidation of all necessary operational licenses and permits for its Chinese subsidiaries. Wuxi Xinzhan Enterprise Management Consulting Co., Ltd. proactively secured a medical device operation permit, underscoring the company's commitment to regulatory foresight.

Regarding liquidity and capital resources, the company's strong cash position of $35.2 million and a favorable current ratio of 2.1x provide substantial financial flexibility. Management deems this liquidity sufficient to support ongoing operations, fund planned capital expenditures for salon expansion, and invest in future R&D initiatives without significant reliance on short-term external financing. The manageable total debt of $18.7 million and a low debt-to-equity ratio of 0.25 further demonstrate a conservative capital structure.

However, the company acknowledges persistent challenges from China's rapidly evolving regulatory landscape, particularly concerning data security, cross-border data transfer, and overseas listings. Navigating these complexities requires continuous monitoring and adaptation, which may lead to increased compliance costs and potential operational uncertainties. Management remains focused on mitigating these risks while pursuing its growth objectives.

Key Risks for Investors: Investing in Park Ha involves significant risks, primarily stemming from its operational base in China and the nature of its business:

• Chinese Regulatory and Policy Risks: The company is highly susceptible to changes in Chinese laws, regulations, and government policies, particularly those affecting the beauty, healthcare, and technology sectors. This includes potential crackdowns on specific industries, which could result in operational restrictions, increased compliance costs, or even forced divestitures.
• Variable Interest Entity (VIE) Structure Risks: Investors do not directly own equity in the operational entities in China. Instead, they hold shares in a Cayman Islands holding company that has contractual arrangements with the VIEs. These contractual arrangements may not be as effective as direct ownership in providing control or enforcing claims. Chinese authorities could deem them illegal or unenforceable, potentially leading to a loss of control over the operating assets.
• Cybersecurity and Data Security Review Uncertainty: While Park Ha currently states it does not meet the criteria for a cybersecurity review under rules effective February 2022 (e.g., it is not an "internet platform operator" with over a million users), the interpretation and scope of these regulations continue to evolve. Future changes or stricter enforcement could subject the company to mandatory reviews, potentially delaying or preventing future overseas capital raises or operations.
• Overseas Listing and Capital Raising Restrictions (CSRC Filings): New rules from March 2023 require Chinese companies to complete specific filings with the China Securities Regulatory Commission (CSRC) for any future overseas stock offerings. Non-compliance could result in substantial fines, operational limitations, or restrictions on Chinese subsidiaries' ability to distribute profits or dividends, severely impacting the company's growth and financial flexibility.
• Cross-Border Data Transfer Regulations: Rules effective March 2023 governing cross-border data handling and transfer introduce complexities and potential compliance burdens. Failure to adhere to these regulations could lead to penalties, reputational damage, or restrictions on data-driven operations.
• Intense Competition: The beauty and medical aesthetics market in China is highly competitive, with numerous domestic and international players. Park Ha faces risks from pricing pressure, rapid technological advancements by competitors, and the need for continuous innovation to maintain market share.
• Product Development and Market Acceptance: Park Ha's success relies on its ability to continuously innovate and develop new biological skincare products and services that gain market acceptance. Failure in R&D or poor market reception of new offerings could negatively impact revenue and profitability.
• Reliance on Key Personnel: The company's success significantly depends on its management team and key scientific personnel. Loss of key individuals without adequate replacement could disrupt operations and strategic execution.

Competitive Landscape: Park Ha operates in China's highly competitive beauty and medical aesthetics market. The company differentiates itself by focusing on proprietary biological technology in product development and its integrated model of R&D, manufacturing, and direct distribution through its salon network. While facing competition from large international cosmetic brands and local beauty service providers, Park Ha aims to carve out a niche by offering scientifically-backed, premium products and personalized services.

Leadership & Strategic Focus: Xiaoqiu Zhang serves as Chief Executive Officer and is the company's primary contact. The current strategy emphasizes continued investment in R&D for new biological skincare formulations, expanding its beauty salon network in key Tier 1 and Tier 2 Chinese cities, and enhancing customer loyalty through personalized service offerings. The company also aims to strengthen its brand presence through targeted marketing campaigns and digital engagement.

Future Outlook & Market Trends: Looking ahead, Park Ha plans to capitalize on China's growing demand for advanced skincare and medical aesthetic services. Key initiatives include expanding its product line with at least two new biological anti-aging solutions in the next fiscal year, opening 5-7 new premium beauty salons in strategic urban centers, and exploring potential partnerships to enhance technological capabilities. The company anticipates continued challenges from China's evolving regulatory landscape, particularly regarding data governance and overseas capital market access. Successfully navigating these regulatory complexities while executing its growth strategy will be critical for Park Ha's sustained performance and investor confidence.